Maryland News Desk

Delveinsight Business Research LLP

DelveInsight’s “Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Immune Thrombocytopenia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Immune Thrombocytopenia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Immune Thrombocytopenia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Immune Thrombocytopenia: An Overview

Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them too quickly.

The word “immune” more accurately describes that Immune Thrombocytopenia is an immunologic disease, where the body destroys its platelets. However, although not all aspects of the pathogenesis of Immune Thrombocytopenia are understood, the disease can no longer be considered idiopathic. In addition, many patients do not have purpura at the time of diagnosis.

Immune Thrombocytopenia is now defined as a quantitative decrease in platelet count related to any immune process. When there is no secondary disease, it is known as primary Immune Thrombocytopenia which accounts for 80% of cases. Common causes of secondary Immune Thrombocytopenia are systemic lupus erythematosus (SLE), drugs, Hepatitis C, human immunodeficiency virus (HIV), Helicobacter Pylori, Chronic Lymphocytic Leukemia, and other lymphoproliferative diseases, the antiphospholipid Syndrome, vaccines (Measles/Mumps/Rubella [MMR] most commonly), and Common Variable Immunodeficiency Disease (CVID) as well as other viruses, post-transfusion purpura, and Evans syndrome. These secondary causes account for approximately 20% of cases of Immune Thrombocytopenia.

The treatment strategies consist of stimulating platelet production to increase the platelet counts, increasing platelet half-life, and decreasing the autoreactive nature of the immune response by targeting the autoreactive antibody production and the platelet destruction.

Further investigations are, however, still needed to better understand the transition toward chronicity and its implication for the treatment response, outcome, and cure for Immune Thrombocytopenia.

Immune Thrombocytopenia Market Key Facts

• The Immune Thrombocytopenia market size in the 7MM was ~USD 3,100 million in 2021.

• In 2021, the US has the largest Immune Thrombocytopenia market size of ~USD 1,860 million among the 7MM countries.

• Among the EU4 countries, Germany had the highest Immune Thrombocytopenia market size in 2021, i.e., ~USD 200 million. The lowest market size was estimated in Spain, with ~USD 130 million in 2021.

• In Japan, the Immune Thrombocytopenia market size was ~USD 290 million in 2021.

• In 2021, the total Immune Thrombocytopenia cases were ~184,000+ in the 7MM. These cases are expected to increase by 2032.

• The United States, in 2021, accounted for the highest number of cases of Immune Thrombocytopenia that were 65,500 cases.

• In 2021, Japan accounted for ~27,200 cases of Immune Thrombocytopenia, which was approximately 15% of the total Immune Thrombocytopenia cases in 7MM.

Immune Thrombocytopenia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Immune Thrombocytopenia pipeline therapies. It also thoroughly assesses the Immune Thrombocytopenia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Immune Thrombocytopenia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Immune Thrombocytopenia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Immune Thrombocytopenia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Immune Thrombocytopenia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Immune Thrombocytopenia Epidemiology, Segmented as –

• Total Diagnosed Prevalent Population of Immune Thrombocytopenia (ITP) in the 7MM [2019–2032]

• Total Prevalent Population of Immune Thrombocytopenia (ITP) in the 7MM [2019–2032]

• Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the 7MM [2019–2032]

Immune Thrombocytopenia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Immune Thrombocytopenia market or expected to be launched during the study period. The analysis covers the Immune Thrombocytopenia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Immune Thrombocytopenia drugs based on their sale and market share.

The report also covers the Immune Thrombocytopenia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Immune Thrombocytopenia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Immune Thrombocytopenia Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market

Immune Thrombocytopenia Therapeutics Analysis

The major goal for the treatment of Immune Thrombocytopenia is to provide a platelet count that prevents major bleeding rather than correcting the platelet count to normal levels. The management of Immune Thrombocytopenia varies widely and current international guidelines recommend several first- and second-line options, including some medicinal products that have not been approved in the EU for this particular condition.

First-line treatment options include corticosteroids, intravenous immunoglobulin (IVIg), and intravenous anti-D immunoglobulin (the latter only for non-splenectomized Rhesus-D positive patients). Patients who fail to respond or who relapse face the option of treatment with second-line drug therapy or splenectomy but there is no clear evidence to support the best approach. Splenectomy can provide long-term efficacy in around 60% of cases. 

Second-line drug therapies for Immune Thrombocytopenia include high-dose dexamethasone or methylprednisolone, high-dose IVIg or anti-D Ig, vinca alkaloids, and danazol, the immunosuppressants cyclophosphamide, azathioprine, and cyclosporine or mycophenolate mofetil, and the anti-CD-20 monoclonal antibody rituximab.

Several major pharma and biotech companies are actively engaged in the development of therapies for Immune Thrombocytopenic Purpura (ITP). Among these, Sanofi stands out as a notable player with drug candidates for ITP in the most advanced stage, namely Phase III clinical trials. This highlights the diverse efforts within the pharmaceutical landscape to address and advance treatments for Immune Thrombocytopenic Purpura, emphasizing the significance of ongoing research and development in this therapeutic area.

Immune Thrombocytopenia Companies Actively Working in the Therapeutics Market Include

Some of the key companies in the Immune Thrombocytopenia therapeutics market include Argenx, Biotest, Cour Pharmaceutical Development, GC Pharma, HanAll Biopharma, Hutchison Medi Pharma, Immunovant, Millennium Pharmaceuticals, Momenta Pharmaceuticals, Principia Biopharma, Sanofi, Takeda, UCB Biopharma, and several others.

Emerging and Marketed Immune Thrombocytopenia Therapies Covered in the Report Include:

• Rilzabrutinib: Sanofi

• Efgartigimod: Argenx

• Mezagitamab: Takeda

• Rozanolixizumab (UCB7665): UCB

• Efgartigimod: arGEN-X

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Immune Thrombocytopenia Competitive Intelligence Analysis

4. Immune Thrombocytopenia Market Overview at a Glance

5. Immune Thrombocytopenia Disease Background and Overview

6. Immune Thrombocytopenia Patient Journey

7. Immune Thrombocytopenia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Immune Thrombocytopenia Treatment Algorithm, Current Treatment, and Medical Practices

9. Immune Thrombocytopenia Unmet Needs

10. Key Endpoints of Immune Thrombocytopenia Treatment

11. Immune Thrombocytopenia Marketed Therapies

12. Immune Thrombocytopenia Emerging Drugs and Latest Therapeutic Advances

13. Immune Thrombocytopenia Seven Major Market Analysis

14. Attribute Analysis

15. Immune Thrombocytopenia Market Outlook (In US, EU5, and Japan)

16. Immune Thrombocytopenia Companies Active in the Market

17. Immune Thrombocytopenia Access and Reimbursement Overview

18. KOL Views on the Immune Thrombocytopenia Market

19. Immune Thrombocytopenia Market Drivers

20. Immune Thrombocytopenia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Galactosemia Market

“Galactosemia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Galactosemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Galactosemia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology